Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1550Terminated 528Recruiting 492Unknown 400Active not recruiting 255Withdrawn 142Not yet recruiting 104Suspended 16Enrolling by invitation 5No longer available 3Available 2Approved for marketing 2

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Tumor-Agnostic 1Dermatologic 1Breast 1

Conditions

Neoplasms 73Breast Neoplasms 73Colorectal Neoplasms 39Prostatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 26Uterine Cervical Neoplasms 20Stomach Neoplasms 20Carcinoma, Hepatocellular 20Pancreatic Neoplasms 15Anxiety Disorders 15Leukemia, Myeloid, Acute 14Hematologic Neoplasms 13Colonic Neoplasms 13Urinary Bladder Neoplasms 12Lymphoma, Follicular 12Brain Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Head and Neck Neoplasms 10Esophageal Neoplasms 10Diabetes Mellitus 10Sarcoma 9Ovarian Neoplasms 9Melanoma 9Liver Neoplasms 9Esophageal Squamous Cell Carcinoma 9Rectal Neoplasms 8Pulmonary Disease, Chronic Obstructive 8Epilepsy 8Disease 8

Interventions

futibatinib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Enrolling by invitation × Neoplasm Metastasis × Clear all
NCT00068003 2026-05-01

Harvesting Cells for Experimental Cancer Treatments

National Institutes of Health Clinical Center (CC)

Enrolling by invitation
7,000 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms

NCT06506955 2026-04-03

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation
15 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06508138 2026-03-06

J21112LINKED

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Enrolling by invitation
24 enrolled

Neoplasm Metastasis, Recurrence

NCT07372261 2026-01-30

PORTENT

Casa Sollievo della Sofferenza IRCCS

Enrolling by invitation
1,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06997458 2025-05-30

LOLA-PROJECT

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Enrolling by invitation
500 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡